Home › Research › Treatments
Perspectives and Insights on Anti-Amyloid Immunotherapy Agents: From Development to Submission of a New Drug Submission (NDS) in Canada
Princy Patel, Aarti Rana, Mayur Pansuria, Rutvik Patel, Hemangini Patel, Peivand Pirouzi. Zenodo (CERN European Organization for Nuclear Research), 2026-07-13
Topic: Amyloid, tau and blood-test diagnosis
Anti-amyloid immunotherapy agents represent a novel and clinically significant class of humanized monoclonal antibodies designed to selectively bind and clear pathological amyloid-beta (Aβ) aggregates from the brain, thereby slowing the progression of early Alzheimer’s disease (AD). Alzheimer’s disease is the leading cause of dementia globally, affecting over 55 million individuals worldwide and nearly 600,000 Canadians, with no previously approved disease-modifying therapy available prior to this class (World Health Organization, 2023; Alzheimer Society of Canada, 2022). This article provides a comprehensive review of anti-amyloid immunotherapy as a therapeutic class, covering its mechanism of action, clinical indications, dosage forms, physicochemical properties, container closure systems, safety profile, and emerging technologies in manufacturing and drug delivery. The article further outlines the preparation of a New Drug Submission (NDS) to Health Canada using the Common Technical Document (CTD) format, with emphasis on class-specific considerations including amyloid biomarker confirmation, amyloid-related imaging abnormality (ARIA) risk management, and biologics-specific quality requirements. Evidence-based recommendations for regulatory professionals are provided.
Key findings
- Anti-amyloid immunotherapy agents represent a novel and clinically significant class of humanized monoclonal antibodies designed to selectively bind and clear pathological amyloid-beta (Aβ) aggregates from the brain, thereby slowing the progression of early Alzheimer’s disease (AD).
Why it matters
This review describes anti-amyloid immunotherapy agents as humanized monoclonal antibodies that bind and clear pathological amyloid-beta aggregates from the brain, thereby slowing progression of early Alzheimer's disease. It covers regulatory considerations including amyloid biomarker confirmation and ARIA risk management for a New Drug Submission to Health Canada.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 26 of the 64 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Zenodo (CERN European Organization for Nuclear Research)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 26 / 64 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 26 of the 64 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Patel, P., Rana, A., Pansuria, M., Patel, R., Patel, H., & Pirouzi, P. (2026). Perspectives and Insights on Anti-Amyloid Immunotherapy Agents: From Development to Submission of a New Drug Submission (NDS) in Canada. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.21339386
Vancouver
Patel P, Rana A, Pansuria M, Patel R, Patel H, Pirouzi P. Perspectives and Insights on Anti-Amyloid Immunotherapy Agents: From Development to Submission of a New Drug Submission (NDS) in Canada. Zenodo (CERN European Organization for Nuclear Research). 2026. doi:10.5281/zenodo.21339386.
BibTeX
@article{patel2026-1f71b223,
author = {Patel, Princy and Rana, Aarti and Pansuria, Mayur and Patel, Rutvik and Patel, Hemangini and Pirouzi, Peivand},
title = {{Perspectives and Insights on Anti-Amyloid Immunotherapy Agents: From Development to Submission of a New Drug Submission (NDS) in Canada}},
journal = {Zenodo (CERN European Organization for Nuclear Research)},
year = {2026},
doi = {10.5281/zenodo.21339386},
url = {https://doi.org/10.5281/zenodo.21339386}
}
Related studies in Treatments
Also in Treatments
166 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.